<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00653796</url>
  </required_header>
  <id_info>
    <org_study_id>P03434</org_study_id>
    <nct_id>NCT00653796</nct_id>
  </id_info>
  <brief_title>Ezetimibe Plus Atorvastatin Versus Atorvastatin in Untreated Subjects With High Cholesterol (P03434)</brief_title>
  <official_title>SCH 58235: A Multicentre, Randomised, Parallel Group, Placebo-Controlled Study Comparing the Efficacy, Safety, And Tolerability of the Daily Co-Administration of Ezetimibe 10 mg With Atorvastatin 10 mg vs. Ezetimibe Placebo With Atorvastatin 10 mg in Untreated Subjects With Primary Hypercholesterolaemia and Coronary Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to assess whether co-administration of ezetimibe 10 mg with
      atorvastatin 10 mg in treatment na√Øve subjects would be more effective than treatment with
      atorvastatin 10 mg alone for reducing LDL-concentrations.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2003</start_date>
  <completion_date type="Actual">August 1, 2004</completion_date>
  <primary_completion_date type="Actual">August 1, 2004</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in LDL-C from baseline to endpoint.</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline to endpoint in total cholesterol, HDL-C and triglycerides.</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: adverse events, laboratory test results, vital signs.</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">148</enrollment>
  <condition>Hypercholesterolemia</condition>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>Ezetimibe + Atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe + Atorvastatin</intervention_name>
    <description>oral tablets: ezetimibe 10 mg + atorvastatin 10 mg once daily for 6 weeks</description>
    <arm_group_label>Ezetimibe + Atorvastatin</arm_group_label>
    <other_name>SCH 58235</other_name>
    <other_name>Zetia</other_name>
    <other_name>Lipitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>oral tablets: atorvastatin 10 mg + ezetimibe placebo once daily for 6 weeks</description>
    <arm_group_label>Atorvastatin</arm_group_label>
    <other_name>Lipitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and non-pregnant female subjects, who demonstrated willingness to participate and
             comply with procedures by signing informed consent, and who were &gt;=18 years and &lt;=75
             years of age, were eligible to participate if they had: a baseline LDL-C concentration
             &gt;=3.3 mmol/L (130 mg/dL) to &lt;=4.9 mmol/L (190 mg/dL); a baseline triglyceride
             concentration of &lt;3.99 mmol/L (350 mg/dL); a documented history of coronary heart
             disease (CHD); a stable weight history for 4 weeks prior to baseline; completion of
             the designated washout periods for all prohibited medications; and did not fulfill any
             of the exclusion criteria for the study.

        Exclusion Criteria:

          -  Body Mass Index of &gt;=30 kg/m^2 at baseline (increased to 35 kg/m^2 in protocol
             amendment 1

          -  Liver transaminase (ALT, AST) &gt;1.5 times the upper limit of normal and with no active
             liver disease at baseline

          -  Evidence of current myopathy (excluding subjects with CK &gt;1.5 times above the upper
             limit of normal at baseline

          -  Clinical lab tests (CBC, blood chemistries, urinalysis) results outside the normal
             range or unacceptable to the investigator at baseline

          -  Type II diabetes mellitus that was poorly controlled (HbA1c&gt;9%), newly diagnosed, or
             changed their anti-diabetic therapy within 3 months of baseline

          -  Type I diabetes mellitus and not on a stable insulin regimen for 3 months prior to
             baseline or who had a recent history of repeated hypoglycaemia or unstable glycaemic
             control

          -  Known hypersensitivity to HMG-CoA reductase inhibitors

          -  Alcohol consumption &gt;14 units (women)/21 units (men) (unit = 0.5 pint of beer or wine,
             or single measure of spirits)

          -  Pregnancy, lactation, or any condition or situation which, in the opinion of the
             investigator, posed a risk to the subject or interfered with participation in this
             study.

          -  Any of the following medical conditions: HIV positive; congestive heart failure
             defined by NYHA as Class III or IV; uncontrolled cardiac arrhythmia; MI, acute
             coronary insufficiency, CABG, or angioplasty within 3 months of baseline; unstable or
             severe peripheral artery disease within 3 months of baseline; newly diagnosed or
             unstable angina pectoris at baseline; uncontrolled hypertension with systolic blood
             pressure &gt;100 mm Hg at baseline; uncontrolled endocrine or metabolic disease known to
             influence serum lipids or lipoproteins; impaired renal function or nephritic syndrome
             at baseline; disorders of the hematological, gastrointestinal, or central nervous
             systems; diseases other than hyperlipidaemia or coronary heart disease that would have
             interfered with study evaluations; and cancer.

          -  Drug abuse or emotional or intellectual problems;

          -  Use of certain drugs, food, or other agents known to alter cholesterol levels or to
             cause pharmacokinetic interactions with either ezetimibe or atorvastatin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <results_reference>
    <citation>Blagden MD, Chipperfield R. Efficacy and safety of ezetimibe co-administered with atorvastatin in untreated patients with primary hypercholesterolaemia and coronary heart disease. Curr Med Res Opin. 2007 Apr;23(4):767-75.</citation>
    <PMID>17407633</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2008</study_first_submitted>
  <study_first_submitted_qc>April 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2008</study_first_posted>
  <last_update_submitted>May 10, 2017</last_update_submitted>
  <last_update_submitted_qc>May 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/policies-perspectives.html</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

